$DCGO

DocGo Inc. (DCGO): Submission of Matters to a Vote of Security Holders

DocGo Inc. (DCGO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dcgo-20260616 0001822359 FALSE 0001822359 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie

Original reporting
Published Jun 18, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$DCGO
Neutral
medium confidence
Mentioned
$DCGO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DCGONeutralLow
01

Why it matters

Shareholders elected two Class II directors, approved advisory executive compensation, and approved a reverse stock split amendment (with the exact ratio to be determined by the board). Other charter amendments (corporate opportunity waiver and officer exculpation) were not approved.

02

Market read

The key tradable item is the approved reverse split authorization; the rest of the votes are governance/audit items with less immediate price impact.

03

What to watch

Traders should wait for the board’s final selection of the exact 1-for-N ratio and any implementation timetable; those details typically drive the real price reaction.

Relevance 6/10Novelty 5/10Timing: after-hours/filing today (2026-06-18) following the June 16 annual meeting

Background

DocGo filed an SEC 8-K reporting results from its June 16, 2026 annual meeting of stockholders (Item 5.07).

Company-level read

Ticker impact

$DCGONeutralMedium confidence
Context

DocGo reported 2026 annual meeting voting results, including shareholder approval of a reverse stock split and other charter amendments.

Expected impact

Near-term volatility possible around implementation details; direction depends on market interpretation of capital-structure intent.

Evidence & confidence

This is a primary SEC filing with concrete outcomes of votes. However, the filing does not provide implementation timing, exact split ratio selection, or any new financial guidance, limiting predictability of magnitude/direction.

Market effects

Reverse-split authorizations can be a read-through for small/mid-cap capital-structure stress, but this filing is company-specific.

Limited; impacts primarily Nasdaq-listed small-cap liquidity and retail/institutional positioning.

Low; no cross-border deal, regulation, or macro linkage disclosed.

Counterpoint

A reverse split authorization can be purely technical (e.g., maintaining listing compliance or simplifying capital structure) rather than a deterioration signal.

Key entities

  • DocGo Inc.

    Nasdaq-listed company whose annual meeting vote outcomes were reported in the 8-K.

  • Reverse stock split amendment

    Charter amendment approved by shareholders authorizing a 1-for-5 to 1-for-10 reverse split ratio to be set by the board.

  • Corporate opportunity amendment

    Charter amendment that shareholders did not approve.

  • Officer exculpation amendment

    Charter amendment that shareholders did not approve.

  • Urish Popeck & Co., LLC

    Ratified as independent registered public accounting firm for year ending Dec. 31, 2026.

Related articles

Med

DocGo Inc. Q2 2026 Earnings Call Summary

DocGo Inc. reported Q2 2026 earnings, highlighting a 19% year-over-year revenue increase in core business lines, despite a $6.3M adjusted EBITDA loss. The company announced its largest acquisition, Hicuity Health, aiming to integrate hospital and home care. Management expects to achieve positive adjusted EBITDA by year-end 2026, with revenue guidance narrowed to $305M-$310M. Cost synergies and efficiency programs are expected to drive future growth.

$DCGOMed

DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast

DocGo (DCGO) shares fell 12.7% pre-market Tuesday after Q2 2026 earnings missed estimates, with a $0.16 loss per share vs. expected $0.10. Revenue was $73.4M, down 8.7% YoY, and the company widened its full-year adjusted EBITDA loss forecast to $17M-$22M. The decline followed the end of migrant-related contracts, though core revenue grew 19%. The stock trades near its 52-week low of $0.451.

$DCGOMed

DocGo Q2 Earnings Call Highlights

DocGo reported record service volumes in Q2, with year-over-year growth across all core businesses. The company acquired Hicuity, assuming $52M in debt and issuing 2% equity. DocGo's revenue rose to $52M in medical transportation but fell in mobile health due to migrant-related work decline. Adjusted EBITDA loss narrowed to $6.3M. The company updated its full-year outlook, expecting a wider EBITDA loss of $17M-$22M. DocGo has $48.1M in cash and expects positive adjusted EBITDA run rate by year-e

$DCGOMed

DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic

DocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved

$DCGOHighAI 9/10

Why is DocGo stock tumbling today?

DocGo (DCGO) shares fell 12.7% pre-open to $0.62 after its Q2 2026 adjusted loss was $0.16 per share versus $0.10 consensus. Revenue was $73.4M, below $75.4M forecast and down 8.7% YoY, tied to wind-down of migrant contracts. It widened FY2026 adjusted EBITDA loss to $17M-$22M and agreed to acquire Hicuity Health (~$65M trailing revenue).